Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference45 articles.
1. Chronic myelogenous leukemia: biology and therapy;Faderl;Ann. Intern. Med.,1999
2. Chronic myeloid leukemia-advances in biology and new approaches to treatment;Goldman;New Engl. J. Med.,2003
3. Molecular mechanisms of transformation by the BCR–ABL oncogene;Sattler;Semin. Hematol.,2003
4. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571;Donato;Blood,2003
5. The development of imatinib as a therapeutic agent for chronic myeloid leukemia;Deininger;Blood,2005
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Starring role of Biomarkers and Anticancer Agents as a Major Driver in Precision Medicine of Cancer Therapy;Current Molecular Medicine;2021-12-21
2. Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia;American Journal of Clinical Oncology;2021-04-16
3. Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study;Therapeutic Drug Monitoring;2019-10
4. Variation in Adherence Measures to Imatinib Therapy;Journal of Global Oncology;2018-12
5. Exploring behaviors, treatment beliefs, and barriers to oral chemotherapy adherence among adult leukemia patients in a rural outpatient setting;BMC Research Notes;2018-11-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3